Ubiquitin-Conjugating Enzyme E2S (UBE2S), A Potential Tumor Therapeutic Target

Jin Cao and Yue-Zu Fan

Department of General Surgery, Tongji Hospital, Tongji University, China

^*Correspondance to: Yue-Zu Fan 

 PDF  Full Text Review Article | Open Access

Abstract:

Objective: The ubiquitin-proteasome system plays important roles in the control of numerous processes including cell-cycle, signal transduction, transcriptional regulation, receptor down regulation, and endocytosis. Ubiquitination is a reversible biochemical process mediated or participated by ubiquitin activating enzyme (E1), ubiquitin-conjugating enzyme (E2), ubiquitin ligase (E3), and 26s proteasome. Dysfunction in several ubiquitin-mediated processes has been shown to cause pathological conditions including malignant transformation. This paper reviews Ubiquitin-conjugating enzyme E2S (UBE2S) as a potential tumor therapeutic target.Methods: In this study, we review the expression of UBE2S in some malignant tumors, its influence on the malignant biological behaviors of cancer and the possible molecular mechanisms in cancer development, according to the related literatures and our recent studies.Results: A growing body of evidence suggests ubiquitination is associated with the tumorigenesis and development of cancer. Recent studies have shown that UBE2S is overexpressed in some malignant tumors such as breast cancer, esophageal cancer, kidney cancer, cervical cancer and gallbladder cancer; and was found associated with the malignant biological behaviors including proliferation, invasion and metastasis of cancer. The related signaling pathways and the possible molecular mechanisms in cancer development were also shown.Conclusions: UBE2S is not only overexpressed in some malignant tumors, but also play a crucial role in tumor growth, invasion and metastasis, thus may be a potential tumor therapeutic target.

Keywords:

Ubiquitination; Ubiquitin-conjugating enzyme; Ubiquitin-conjugating enzyme E2S; Cancer

Cite the Article:

Cao J, Fan Y-Z. Ubiquitin-Conjugating Enzyme E2S (UBE2S), A Potential Tumor Therapeutic Target. Clin Oncol. 2016; 1: 1132.